About Cerus (NASDAQ:CERS)
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:CERS
CUSIP15708510
Phone925-288-6000
Debt
Debt-to-Equity Ratio0.77%
Current Ratio3.89%
Quick Ratio3.26%
Price-To-Earnings
Trailing P/E Ratio-9.80
Forward P/E Ratio-12.20
P/E GrowthN/A
Sales & Book Value
Annual Sales$43.57 million
Price / Sales16.33
Cash FlowN/A
Price / CashN/A
Book Value$0.34 per share
Price / Book16.15
Profitability
EPS (Most Recent Fiscal Year)($0.56)
Net Income$-60,580,000.00
Net Margins-139.06%
Return on Equity-154.46%
Return on Assets-66.63%
Miscellaneous
Employees215
Outstanding Shares129,600,000
Cerus (NASDAQ:CERS) Frequently Asked Questions
What is Cerus' stock symbol?
Cerus trades on the NASDAQ under the ticker symbol "CERS."
How were Cerus' earnings last quarter?
Cerus Co. (NASDAQ:CERS) announced its quarterly earnings results on Thursday, March, 8th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.11) by $0.01. The biotechnology company had revenue of $16.20 million for the quarter, compared to the consensus estimate of $17.53 million. Cerus had a negative return on equity of 154.46% and a negative net margin of 139.06%. The business's revenue was up 60.4% compared to the same quarter last year. During the same period last year, the business posted ($0.13) EPS. View Cerus' Earnings History.
When is Cerus' next earnings date?
What price target have analysts set for CERS?
4 brokers have issued 1-year price targets for Cerus' stock. Their forecasts range from $5.00 to $6.00. On average, they anticipate Cerus' share price to reach $5.25 in the next year. View Analyst Ratings for Cerus.
What are Wall Street analysts saying about Cerus stock?
Here are some recent quotes from research analysts about Cerus stock:
- 1. According to Zacks Investment Research, "Cerus Corporation is developing medical products based on a platform technology that prevents nucleic acid replication. The company's initial application of this technology is the development of systems to inactivate viruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. " (4/13/2018)
- 2. Cantor Fitzgerald analysts commented, "This afternoon, CERS announced that its Ph 3 transfusion study (SPARC) evaluating its INTERCEPT-treated red blood cells in thalassemia (chronic anemia) patients achieved its primary efficacy and safety endpoints." (1/23/2018)
Who are some of Cerus' key competitors?
Some companies that are related to Cerus include Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), OraSure Technologies (OSUR), Glaukos (GKOS), Luminex (LMNX), K2M Group (KTWO), MiMedx Group (MDXG), CryoLife (CRY), LeMaitre Vascular (LMAT), Cardiovascular Systems (CSII), AtriCure (ATRC), AngioDynamics (ANGO), Anika Therapeutics (ANIK), Tactile Systems Technology (TCMD), SurModics (SRDX), Inovio Pharmaceuticals (INO) and Accuray (ARAY).
Who are Cerus' key executives?
Cerus' management team includes the folowing people:
- Mr. William M. Greenman, Pres, CEO & Director (Age 51)
- Dr. Laurence M. Corash M.D., Co-Founder, Chief Scientific Officer, Sr. VP & Corp. Director (Age 74)
- Mr. Kevin D. Green, VP of Fin. & CFO (Age 46)
- Dr. Richard J. Benjamin MBChB, Ph.D., Chief Medical Officer (Age 58)
- Mr. Vivek K. Jayaraman, Chief Commercial Officer (Age 43)
Has Cerus been receiving favorable news coverage?
News coverage about CERS stock has trended somewhat positive this week, Accern reports. Accern identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cerus earned a coverage optimism score of 0.20 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 46.82 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Cerus?
Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cerus' stock price today?
One share of CERS stock can currently be purchased for approximately $5.49.
How big of a company is Cerus?
Cerus has a market capitalization of $730.93 million and generates $43.57 million in revenue each year. The biotechnology company earns $-60,580,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Cerus employs 215 workers across the globe.
How can I contact Cerus?
Cerus' mailing address is 2550 STANWELL DRIVE, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]
MarketBeat Community Rating for Cerus (CERS)
MarketBeat's community ratings are surveys of what our community members think about Cerus and other stocks. Vote "Outperform" if you believe CERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CERS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cerus (NASDAQ:CERS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Cerus in the last 12 months. Their average twelve-month price target is $5.25, suggesting that the stock has a possible downside of 4.37%. The high price target for CERS is $6.00 and the low price target for CERS is $5.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.75 | 2.75 | 2.80 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $5.25 | $5.25 | $6.20 | $7.00 |
| Price Target Upside: | 4.37% downside | 7.80% upside | 61.46% upside | 131.79% upside |
Cerus (NASDAQ:CERS) Consensus Price Target History
Cerus (NASDAQ:CERS) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Cerus (NASDAQ:CERS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Cerus (NASDAQ CERS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.40%
Institutional Ownership Percentage: 51.93%
Cerus (NASDAQ CERS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/15/2018 | Laurence M Corash | Insider | Buy | 150,011 | $5.15 | $772,556.65 | 1,462,580 |  |
| 3/13/2018 | Carol Moore | SVP | Sell | 2,623 | $5.05 | $13,246.15 | | |
| 3/12/2018 | Chrystal Menard | insider | Sell | 1,960 | $4.80 | $9,408.00 | 4,832 | |
| 3/12/2018 | Kevin Dennis Green | CFO | Sell | 2,063 | $4.80 | $9,902.40 | 58,062 | |
| 3/12/2018 | William Mariner Greenman | CEO | Sell | 7,735 | $4.80 | $37,128.00 | | |
| 8/11/2017 | Laurence M Corash | Insider | Buy | 92,796 | $2.45 | $227,350.20 | 1,375,711 | |
| 3/15/2017 | Kevin Dennis Green | CFO | Sell | 2,343 | $4.21 | $9,864.03 | | |
| 3/15/2017 | William Mariner Greenman | Insider | Sell | 8,786 | $4.21 | $36,989.06 | | |
| 3/14/2017 | Carol Moore | SVP | Sell | 2,377 | $4.15 | $9,864.55 | | |
| 3/14/2017 | Richard J Benjamin | Insider | Sell | 1,189 | $4.15 | $4,934.35 | 3,000 | |
| 8/22/2016 | Kevin Dennis Green | CFO | Sell | 17,150 | $6.80 | $116,620.00 | | |
| 8/19/2015 | Laurence M Corash | Insider | Buy | 25,900 | $4.99 | $129,241.00 | 1,270,256 | |
| 8/18/2015 | Laurence M Corash | Insider | Buy | 84,600 | $4.77 | $403,542.00 | | |
| 11/10/2014 | William Mariner Greenman | CEO | Buy | 21,800 | $3.93 | $85,674.00 | | |
| 11/19/2012 | William Mariner Greenman | CEO | Buy | 3,200 | $3.02 | $9,664.00 | | |
| 11/16/2012 | Laurence M Corash | Insider | Buy | 2,000 | $2.85 | $5,700.00 | | |
| 11/16/2012 | William Mariner Greenman | CEO | Buy | 13,800 | $2.85 | $39,330.00 | | |
(Data available from 1/1/2013 forward)
Cerus (NASDAQ CERS) News Headlines
| Source: |
|
Cerus (NASDAQ:CERS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cerus (NASDAQ:CERS) Income Statement, Balance Sheet and Cash Flow Statement
Cerus (NASDAQ CERS) Stock Chart for Friday, April, 20, 2018
Loading chart…
